Clinical trial NCT06587737: Colchicine for the Reduction of Dependency and Vascular Events After an Acute Intracerebral Hemorrhage
Official title: A Double-blind, Randomized, Placebo-controlled, Phase III Study for Reducing Dependency and Cardiovascular Events with Oral Colchicine 0.5mg Once Daily Compared with Placebo in Participants with Spontaneous Intracerebral Hemorrhage and Established, or Risk Factors For, Atherosclerosis
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE3
Conditions: Colchicine
ICH - Intracerebral Hemorrhage
Stroke
Dependence
Lead sponsor: Population Health Research Institute
Sponsor class: OTHER
First posted: 2024-09-19
Enrollment: 1125
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Double-blind, randomized, placebo-controlled, phase III study
Primary purpose: PREVENTION

Brief summary: Data indicate that patients with intracerebral hemorrhage (ICH) are at high risk for thromboembolic events and disability that is not being sufficiently mitigated by current treatment strategies. This is aggravated by the cessation of antithrombotic medications for significant periods after hemorrhage. These findings highlight the need for novel treatments that modify the high risk for major vascular events and functional outcomes in ICH survivors.

The objective of CoVasc-ICH 2 is to demonstrate that oral colchicine 0.5 mg daily is superior to placebo for improving the outcomes of ICH survivors with evidence or risk factors for atherosclerosis, when started within 72 hours from ICH onset.


Eligibility criteria: Inclusion Criteria:

Adult patients presenting with spontaneous intraparenchymal hemorrhage within 72 hours of symptom onset and qualifying for at least one of the following categories:

i. history of symptomatic coronary, peripheral and/or carotid artery disease (severe atherosclerotic vascular disease), or ii. visualized extracranial cervical/intracranial atherosclerotic disease causing any degree of stenosis/occlusion or presence of aortic arch plaque with maximum thickness ≥1 mm (moderate atherosclerotic vascular disease), or iii. two or more risk factors including: age 60 years or older, hypertension, dyslipidemia, diabetes mellitus, chronic kidney disease (eGFR: 15-50mL/min), history of ischemic stroke or current smoking (mild atherosclerotic vascular disease).

Exclusion Criteria:

* secondary causes of ICH (such as trauma, macrovascular anomalies, neoplasms or bleeding diathesis)
* ICH volume more than 60ml in the last imaging scan prior to consent
* Glasgow Coma Scale (GCS) score less than 7 or being intubated at the time of consent
* inflammatory bowel disease or chronic diarrhea
* cirrhosis or severe hepatic dysfunction
* renal insufficiency (eGFR\<15mL/min)
* concurrent or planned treatment with strong CYP3A4 inhibitors (atazanavir, clarithromycin, darunavir/ritonavir, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, tipranavir/ritonavir) or P-gp inhibitors (cyclosporine, ranolazine)
* pregnancy or breast-feeding
* known allergy or sensitivity to colchicine
* a strong indication for colchicine where assignment to placebo is deemed unacceptable
* estimated life expectancy less than 6 months at the time of enrollment, and
* inability to adhere to study procedures

Primary outcomes:
measure: Efficacy: MACE and Dependency
timeFrame: through study completion, an average of 36 months
measure: Safety: Symptomatic hematoma expansion, major gastrointestinal adverse reactions or infection rates
timeFrame: through study completion, an average of 36 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Population Health Research Institute, Hamilton Health Sciences, McMaster University
name: Aristeidis Katsanos, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Population Health Research Institute, Hamilton Health Sciences, McMaster University
name: Ashkan Shoamanesh, MD
role: PRINCIPAL_INVESTIGATOR
References: